Interactive Association Between Intronic Polymorphism (rs10506151) of the LRRK2 Gene and Type 2 Diabetes on Neurodegenerative Diseases

References

• Wu S, Bekhit AE-DA, Wu Q, et al. Bioactive peptides and gut microbiota: candidates for a novel strategy for reduction and control of neurodegenerative diseases. Trends Food Sci Technol. 2020.
   Web of Science ®Google Scholar
• Muddapu VR, Dharshini SAP, Chakravarthy VS, Gromiha MM. Neurodegenerative Diseases – is Metabolic Deficiency the Root Cause? Front Neurosci. 2020;14:213. doi:10.3389/fnins.2020.00213
   PubMed Web of Science ®Google Scholar
• Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer’s disease and Parkinson’s disease. Drug Des Devel Ther. 2017;11:797–810. doi:10.2147/DDDT.S130514
   PubMed Web of Science ®Google Scholar
• Bivona G, Gambino CM, Iacolino G, Ciaccio M. Vitamin D and the nervous system. Neurol Res. 2019;41(9):827–835. doi:10.1080/01616412.2019.1622872
   PubMed Web of Science ®Google Scholar
• Sheikh S, Safia HE, Mir SS. Neurodegenerative Diseases: multifactorial Conformational Diseases and Their Therapeutic Interventions. J Neurodegenerative Dis. 2013;2013:563481. doi:10.1155/2013/563481
   PubMedGoogle Scholar
• García J-C, Bustos R-H. The Genetic Diagnosis of Neurodegenerative Diseases and Therapeutic Perspectives. Brain Sci. 2018;8(12):222. doi:10.3390/brainsci8120222
   Web of Science ®Google Scholar
• Rui Q, Ni H, Li D, Gao R, Chen G. The Role of LRRK2 in Neurodegeneration of Parkinson Disease. Curr Neuropharmacol. 2018;16(9):1348–1357. doi:10.2174/1570159X16666180222165418
   PubMed Web of Science ®Google Scholar
• Chen X, Xie C, Tian W, et al. Parkinson’s disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging. Mol Neurodegener. 2020;15(1):12. doi:10.1186/s13024-020-00360-0
   PubMed Web of Science ®Google Scholar
• Rudenko IN, Kaganovich A, Langston RG, et al. The G2385R risk factor for Parkinson’s disease enhances CHIP-dependent intracellular degradation of LRRK2. Biochem J. 2017;474(9):1547–1558. doi:10.1042/BCJ20160909
   Web of Science ®Google Scholar
• Skipper L, Li Y, Bonnard C, et al. Comprehensive evaluation of common genetic variation within LRRK2 reveals evidence for association with sporadic Parkinson’s disease. Hum Mol Genet. 2005;14(23):3549–3556. doi:10.1093/hmg/ddi376
   Web of Science ®Google Scholar
• Toft M, Haugarvoll K, Ross OA, Farrer M, Aasly J. LRRK2 and Parkinson’s disease in Norway. Acta Neurol Scand. 2007;115:72–75. doi:10.1111/j.1600-0404.2007.00852.x
   Web of Science ®Google Scholar
• Morsi M, Maher A, Aboelmagd O, Johar D, Bernstein L. A shared comparison of diabetes mellitus and neurodegenerative disorders. J Cell Biochem. 2018;119(2):1249–1256. doi:10.1002/jcb.26261
   PubMed Web of Science ®Google Scholar
• Xu Q, Park Y, Huang X, et al. Diabetes and risk of Parkinson’s disease. Diabetes Care. 2011;34(4):910–915. doi:10.2337/dc10-1922
   PubMed Web of Science ®Google Scholar
• Pagano G, Polychronis S, Wilson H, et al. Diabetes mellitus and Parkinson disease. Neurology. 2018;90(19):e1654–e1662. doi:10.1212/WNL.0000000000005475
   PubMed Web of Science ®Google Scholar
• Biosa A, Outeiro TF, Bubacco L, Bisaglia M. Diabetes mellitus as a risk factor for Parkinson’s disease: a molecular point of view. Mol Neurobiol. 2018;55(11):8754–8763. doi:10.1007/s12035-018-1025-9
   PubMed Web of Science ®Google Scholar
• Li Y, Li L, Hölscher C. Incretin-based therapy for type 2 diabetes mellitus is promising for treating neurodegenerative diseases. Rev Neurosci. 2016;27(7):689–711.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Tanaka K, Fukushima W, et al. Case–control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci. 2010;293(1–2):82–86. doi:10.1016/j.jns.2010.03.002
   PubMed Web of Science ®Google Scholar
• Zhu Y, Ding X, She Z, et al. Exploring shared pathogenesis of Alzheimer’s disease and type 2 diabetes mellitus via co-expression networks analysis. Curr Alzheimer Res. 2020;17(6):566–575. doi:10.2174/1567205017666200810164932
   PubMed Web of Science ®Google Scholar
• Lin W-Y, Liu Y-L, Yang AC, Tsai S-J, Kuo P-H. Active cigarette smoking is associated with an exacerbation of genetic susceptibility to diabetes. Diabetes. 2020;69(12):2819–2829. doi:10.2337/db20-0156
   Web of Science ®Google Scholar
• Turner ST, Fornage M, Jack CR, et al. Genomic susceptibility loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships. Arch Neurol. 2009;66(7):847–857. doi:10.1001/archneurol.2009.110
   Google Scholar
• Seshadri S, DeStefano AL, Au R, et al. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet. 2007;8(S1):S15. doi:10.1186/1471-2350-8-S1-S15
   Web of Science ®Google Scholar
• Kuan Y-C, Huang K-W, Lin C-L, Hu C-J, Kao C-H. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79:77–83. doi:10.1016/j.pnpbp.2017.06.002
   PubMed Web of Science ®Google Scholar
• Wahlqvist ML, Lee M-S, Hsu -C-C, Chuang S-Y, Lee J-T, Tsai H-N. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18(6):753–758. doi:10.1016/j.parkreldis.2012.03.010
   PubMed Web of Science ®Google Scholar
• Rotermund C, Machetanz G, Fitzgerald JC. The Therapeutic Potential of Metformin in Neurodegenerative Diseases. Front Endocrinol (Lausanne). 2018;9:400.
   PubMed Web of Science ®Google Scholar
• Orkaby AR, Cho K, Cormack J, Gagnon DR, Driver JA. Metformin vs sulfonylurea use and risk of dementia in US veterans aged≥ 65 years with diabetes. Neurology. 2017;89(18):1877–1885. doi:10.1212/WNL.0000000000004586
   PubMed Web of Science ®Google Scholar
• Asadbegi M, Yaghmaei P, Salehi I, Ebrahim-Habibi A, Komaki A. Neuroprotective effects of metformin against Aβ-mediated inhibition of long-term potentiation in rats fed a high-fat diet. Brain Res Bull. 2016;121:178–185. doi:10.1016/j.brainresbull.2016.02.005
   PubMed Web of Science ®Google Scholar
• Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes. Neuropharmacology. 2011;60(6):910–920. doi:10.1016/j.neuropharm.2011.01.033
   PubMed Web of Science ®Google Scholar
• Markowicz-Piasecka M, Sikora J, Szydłowska A, Skupień A, Mikiciuk-Olasik E, Huttunen KM. Metformin–a future therapy for neurodegenerative diseases. Pharm Res. 2017;34(12):2614–2627. doi:10.1007/s11095-017-2199-y
   PubMed Web of Science ®Google Scholar
• Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of Alzheimer’s disease: a population‐based case–control study. J Am Geriatr Soc. 2012;60(5):916–921.
   PubMed Web of Science ®Google Scholar